HPLC-MS analysis reveals blood monitoring as 'essential' for generic tacrolimus recipients
Aug 20 2010
Tacrolimus is used to suppress the immune response in individuals after they receive a transplanted organ, to prevent their body from rejecting the alien tissue.
Findings presented at the International Congress of the Transplant Society (ICTS) reveal that a recently approved generic version of the drug is safe for use in recipients of kidneys and liver tissue.
However, the HPLC-MS analysis indicated a need to assess concentrations of the drug in the bloodstream of patients.
Some 37 per cent of participants experienced a shift in concentration of more than a fifth after changing to the generic drug.
Across the board, the reduction in tacrolimus concentration averaged 15 per cent, the scientists saw.
The ICTS event took place in Vancouver, Canada on August 15th-19th.
Chromatography Today - Buyers' Guide 2022
In This Edition Modern & Practocal Applications - Accelerating ADC Development with Mass Spectrometry - Implementing High-Resolution Ion Mobility into Peptide Mapping Workflows Chromatogr...
View all digital editions
ACS National Meeting & Expo, Spring 2023
Mar 26 2023 Indianapolis, IN, USA
Apr 18 2023 Kintex, South Korea
Apr 19 2023 Ho Chi Minh City, Vietnam
Apr 30 2023 Dublin, Ireland & Online
Apr 30 2023 Denver, CO, USA